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Abstract
Background In view of the increased use of metformin in
obese adolescents, the aim of this study was to determine
the pharmacokinetics of metformin in overweight and
obese adolescents.
Methods In overweight and obese adolescents receiving
metformin 500 or 1000 mg twice daily for 37 weeks during
a clinical trial, blood samples were collected over 8 h
during an oral glucose tolerance test. Population pharma-
cokinetic modeling was performed using NONMEM.
Results Data for 22 overweight and obese adolescents with
a mean total body weight (TBW) of 79.3 kg (range
54.7–104.9), body mass index (BMI) of 29.1 kg/m2 (range
22.9–39.3), and age of 15.9 years (range 11.1–17.5) were
analysed. In the model, oral clearance (CL/F) of metformin
(1.17 l/min [relative standard error of 6%]) increased
significantly with TBW (p\ 0.01). More specifically, CL/
F increased with both developmental weight
(WTfor age and length) and excess body weight (WTexcess), for
which an excess weight covariate model was proposed.
Conclusion The CL/F of metformin in obese adolescents
(1.17 l/min) is larger than that in non-obese children
(0.55 l/min) and similar to that in adults (1.3 l/min) as
reported in the literature. This increase may potentially be
explained by increased tubular secretion of metformin.
These results appear to indicate that adult dosages of
metformin could be considered in obese adolescents if
pediatric dosages have been therapeutically ineffective.
ClinicalTrials.gov NCT01487993.
Key Points
Oral clearance (CL/F) of metformin increases
significantly with total body weight (TBW) in
overweight and obese adolescents.
The CL/F in obese adolescents is higher than in non-
obese children and comparable to adult values
reported in the literature.
These results indicate that adult dosages of
metformin (i.e., 3 g per day) could be considered in
obese adolescents if pediatric dosages have been
therapeutically ineffective.
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1 Introduction
Worldwide prevalence rates of obesity are increasing, and
this is not only restricted to adults. In the USA, 34.5% of
adolescents (aged 12–19 years) were overweight (body
mass index [BMI] for age C 85th percentile) and 20.5%
were obese (BMI for age C 95th percentile) in 2011–2012
[1]. In Western Europe, prevalence rates of obesity (based
on International Obesity Task Force cut-offs) ranged from
3.8 to 13.5%, whereas percentages in North Africa and the
Middle East ranged from 4.2 to 23.3% in boys and girls
(aged\ 20 years) in 2013 [2]. Obesity is the most com-
mon cause of insulin resistance in children and adolescents
[3] and a known risk factor for type 2 diabetes mellitus
(T2DM) [4]. Metformin is a registered drug for the treat-
ment of T2DM in pediatric patients aged [ 10 years.
Recently, a large increase in prescriptions of metformin or
other oral antidiabetic drugs was observed in children
[5, 6], suggesting that metformin is prescribed not only in
children with T2DM but also in obese children with type 1
diabetes mellitus in addition to insulin and for obesity with
or without insulin resistance [5]. To date, except for one
abstract of a study in obese adolescents with T2DM [8], the
pharmacokinetics of metformin have only been studied in
non-obese children who received metformin for early-
normal onset of puberty [7]. While tubular secretion is the
primary route of elimination, conducted by organic cation
transporters (OCT2) (basolateral membrane of the renal
tubule cells; uptake of metformin in the renal tubule cells)
and human multidrug and toxin extrusion transporters (i.e.,
MATE1 and MATE2K) (apical membrane of the renal
tubules; transports metformin out of the tubule cells)
[9, 10], the influence of obesity on the expression or
activity of these renal transporters is largely unknown. The
OCT1 transporter is expressed on the apical membrane of
the renal tubule and may play a role in the reabsorption of
metformin [9]. The aim of this study was to determine the
pharmacokinetics of metformin in overweight and obese
adolescents enrolled in a multicentre randomized double-
blind controlled trial investigating the short- and long-term
efficacy and safety outcomes of metformin [11].
2 Methods
2.1 Patients
The clinical trial protocol of the multicentre randomized
double-blind controlled study on short- and long-term
efficacy and safety outcomes of metformin are described
elsewhere [11] and repeated briefly here as relevant to this
pharmacokinetic sub-study. Obese adolescents were
recruited at the pediatric outpatient clinic of the St. Anto-
nius Hospital Nieuwegein and Jeroen Bosch Hospital in ‘s-
Hertogenbosch, the Netherlands. Patients were eligible for
inclusion if they were aged 10–16 years, obese (defined as
BMI-standard deviation score [SDS] [ 2.3 at pre-study
screening), insulin resistant (defined as homeostatic model
assessment—insulin resistance [HOMA-IR] C 3.4 at pre-
study screening), and of Caucasian descent. Patients were
excluded if they had T2DM, polycystic ovary syndrome, or
endocrine disorders for which treatment with corticos-
teroids was indicated. Also excluded were patients with a
height B 1.3 standard deviation (SD) of target height,
(history of) alcohol abuse, impaired renal function
(glomerular filtration rate [GFR]\ 80 ml/min), or
impaired hepatic function (alanine aminotransferase
[ALT][ 150% of normal value for age) and patients who
used anti-hyperglycemic drugs or who were pregnant.
Before participation, parents and patients provided written
informed consent and assent, respectively. The study was
approved by the local human research and ethics commit-
tee of the St. Antonius Hospital (VCMO, NL34611.100.11)
and was conducted in accordance with the principles of the
Declaration of Helsinki and the Medical Research Involv-
ing Human Subjects Act (WMO) of the Netherlands.
2.2 Study Design
In this multicentre randomized double-blind trial
(NCT01487993 and EudraCT 2010-023980-17), 23 over-
weight and obese adolescents of the metformin arm par-
ticipated in the pharmacokinetic study, which was
performed during an oral glucose tolerance test (OGTT).
At the time of the pharmacokinetic sub-study, patients had
received metformin 500 or 1000 mg (Centrapharm, Etten
leur, the Netherlands) twice daily for 37 weeks [11].
Patients were asked to fast overnight and postpone their
morning metformin dose until arrival at the outpatient
clinic. After insertion of a venous cannula, patients
received a solution of glucose 1.75 g/kg body weight
(maximum 75 g) dissolved in 200 or 300 ml of water.
Directly after ingestion of the glucose solution, the met-
formin tablet was ingested (500 or 1000 mg). Blood sam-
ples were collected before the metformin dose (trough
concentration) and at 60, 120, 240, 360, and 480 min,
centrifuged at 4000 RPM (g) for 5 min and stored at -
20 C until analysis. In addition, blood samples for crea-
tinine, ALT, and DNA to determine the genetic variation in
the OCT1 and MATE1 transporters were collected.
2.3 Drug Assay
Serum metformin concentrations were quantified using
high-performance liquid chromatography (HPLC). For
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sample preparation, 50 ll of internal standard (phenformin
500 mg/l in methanol) and 250 ll of acetonitrile were
added to 100 ll of the sample. After vortex mixing, this
mixed sample was centrifuged at 4000g for 10 min. Ten
microliter of the supernatant was injected into the HPLC
column (Zorbax SB-CN 5 lm 4.6 9 150 mm [Agilent]),
protected by a precolumn (H3-10C5 [Hichrom]), which
was kept at 30 C and detected by a photodiode array
detector (234 nm). Isocratic elution was performed with a
mobile phase consisting of sodium sulphate (pH of 2.3) and
acetonitrile in a 770:230 ratio at a flow rate of 1.2 ml/min.
The elution times for metformin and the internal standard
were 2.1 and 3.0 min, respectively. The assay was linear
over 0.2–5.0, and 0.2 mg/l was the limit of quantification
(LOQ). Intra- and inter-assay coefficients of variation were
within 0.8–3.6 and 4–8.5%, respectively. The concentra-
tions of the quality controls were 0.5, 2.5, and 4.5 mg/l
(low, middle and high, concentration, respectively).
2.4 DNA Analysis
DNA was isolated from whole blood on the MagNA Pure
LC 2.0 instrument (Roche). Ready-made TaqMan assays
were used for determination of OCT1 (rs72552763,
rs12208357, rs34130495, rs34059508, and rs622342) and
MATE1 (rs2289669, rs10735) polymorphisms on the ABI
PRISM 7500 Real-Time polymerase chain reaction sys-
tem (Applied Biosystems, Bleiswijk, the Netherlands).
Violation of Hardy–Weinberg (HW) equilibrium was tes-
ted with the Chi squared test. In addition, observed minor
allele frequencies were compared with the frequencies
found in the single nucleotide polymorphism (SNP) data-
base of the National Center for Biotechnology Information.
The OCT1 haplotype, defined by the presence of one or
more of the genetic variants rs72552763, rs12208357,
rs34130495, and rs34059508 was estimated with the hap-
lo.stats package (R, version 3.1.1), which uses the expec-
tation–maximization logarithm and a posterior
probability[ 0.98.
2.5 Statistical Analysis
The area under the curve concentrations from 0 to 8 h after
dose (AUC0–8h) and AUC until infinity (AUCinf) for met-
formin were calculated for each patient separately using the
linear trapezoidal rule in R software (version 3.0.1) [12].
Seven patients had metformin concentrations measured
until 7 h post-dose and for these patients the AUC0–8h was
calculated based on extrapolation until 8 h. The calculated
AUC0–8h and AUCinf were standardized for the adminis-
tered dose (1000 mg), as patients received metformin 500
or 1000 mg. The Pearson correlation test was applied to
test the correlation between total body weight (TBW) and
dose-standardized AUC0–8h and AUCinf. The Mann–
Whitney test or Kruskal–Wallis test was applied to test
statistical differences in dose-standardized AUC0–8h or
dose-standardized AUCinf and different genotype groups of
the OCT1 and MATE1 transporter. Statistical analyses
were performed using IBM SPSS software, version 22.
2.6 Population Pharmacokinetic Analysis
and Internal Model Validation
Metformin data were analyzed using non-linear mixed
effects modeling with NONMEM (version 7.2; ICON
Development Solutions, Hanover, MD, USA) [13]. Pirana
(2.9.1) [14], R (3.0.1) [12], Xpose (4.5.0) [14], and Psn
(3.6.2) [14] were used to evaluate and visualize the data. Of
the 129 metformin samples, seven trough samples (5.4%)
and one post-dose sample (at 8 h; 0.8%) were below the
LOQ. One trough sample below the LOQ of 0.2 mg/l (i.e.,
0.12 mg/l) was kept in the dataset, whereas no metformin
could be detected for the other samples below LOQ, so
these samples were subsequently removed from the anal-
ysis [15, 16]. The first-order conditional estimation method
with interaction was used for model development. Dis-
crimination between different models was guided by the
likelihood ratio test, by comparison of the objective func-
tion value (OFV, i.e., - 2 log likelihood [- 2LL]) between
nested models. A p value of\ 0.05, representing a
decrease of 3.84 in OFV for one degree of freedom, was
considered statistically significant. In addition, goodness-
of-fit plots for metformin (observed vs. individual pre-
dicted concentrations, observed vs. population predicted
concentrations, conditional weighted residuals vs. time
after dose, and conditional weighted residuals vs. popula-
tion predicted concentrations plots) were used for diag-
nostic purposes. Furthermore, precision of parameter
estimates, the correlation matrix, and visual improvement
in the individual plots were used to evaluate the model.
Pharmacokinetic models incorporating either one or two
compartments with first-order, zero-order, or combined
first- and zero order oral absorption were tested. Further-
more, the addition of one or more transit compartments
[17] or an oral absorption lag time was evaluated.
Interindividual variability (IIV) was assumed to follow a
log-normal distribution. Residual variability was tested
using proportional, additive, or combined proportional and
additive error models for metformin. For internal model
evaluation, we used a bootstrap resampling method using
1000 replicates and prediction-corrected visual predictive
check (pcVPC) [18] using 1000 simulated datasets of
individuals from the original dataset.
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2.7 Covariate Model
Tested covariates were TBW, BMI, BMI-SDS, lean body
weight (LBW) according to the equations of Janmahasatian
et al. [19], Foster et al. [20] and Peters et al. [21] and
waist–hip ratio, age, sex, creatinine, and estimated GFR
(eGFR) according to the bedside Schwartz formula [22]. In
addition, the influence of genetic polymorphisms of the
OCT1 and MATE1 transporter were tested. Covariates
were plotted independently against the eta (g) estimates of
the pharmacokinetic parameters to visualize potential
relations. Continuous covariates were tested using linear
and power equations (Eqs. 1, 2):
Pi ¼ Pp  ð1þ V  ðCOV  COVmedianÞÞ ð1Þ
Pi ¼ Pp  ðCOV=COVmedianÞW ; ð2Þ
where Pi and Pp represent individual and population
parameter estimates, respectively, COV represents the
covariate, COVmedian represents the median value of the
covariate for the population, V represents a correlation
factor between the population pharmacokinetic parameter
and the change in covariate value for a linear function, and
W represents the exponent for a power function. The cat-
egorical covariates sex and genetic polymorphisms of the
OCT1 and MATE1 transporter were examined by calcu-
lating a separate parameter for each category of the
covariate. Based on OCT1 (rs622342) and MATE1
(rs2289669 and rs10735) genotype, subjects were catego-
rized into two groups: variants (homozygous and
heterozygous variants) or wild types. For OCT1 haplotype,
subjects were categorized as normal transporter activity or
decreased and absent transporter activity. In addition, dif-
ferent combinations of the genotypes were tested, for
example between the OCT1 (rs622342) and MATE1
(rs2289669) transporter [23].
Potential covariates were entered into the model one at a
time and statistically tested using the likelihood ratio test.
In addition, if applicable, reduction in IIV (omega [x]) of
the parameter was evaluated upon inclusion of the
covariate on the parameter. Further, trends in the random
effects of the parameter versus the covariate involved were
observed. Finally, after forward inclusion (p\ 0.05), a
backward exclusion procedure was applied to justify the
inclusion of a covariate (p\ 0.01). The choice of the final
covariate model was further evaluated as discussed in
Sect. 2.6.
2.8 Excess Weight Covariate Model
To further analyze the influence of (over)weight on the
pharmacokinetics of metformin, an excess weight model
was tested for the parameters for which TBW proved a
covariate given the criteria described in Sect. 2.6. Using
this covariate model, the TBW of each individual patient
was considered to be composed of two parts: develop-
mental weight (WTfor age and length) and excess body weight
(WTexcess) [24], whereas separate functions for each of
these weights were used.
For each individual patient in the study,
WTfor age and length was derived from the Dutch TNO growth
calculator [25] on the basis of the length and age of the
patient at a BMI-SDS score of 0 (no overweight) [25].
WTexcess and relative WTexcess (%WTexcess) were calcu-
lated using Eqs. (3) and (4), respectively, for each indi-
vidual patient:
WTexcess ¼ TBW WTfor age and length ð3Þ
%WTexcess ¼ ðWTexcess=WTfor age and lengthÞ  100%: ð4Þ
First, WTfor age and length, WTexcess, and %WTexcess were
all plotted independently against the eta estimate of the
pharmacokinetic parameter of interest to visualize the
relation.
The separate impact of WTfor age and length and WTexcess
on clearance in adolescents was evaluated using Eqs. (5)
and (6):
CLnonobese adolescent ¼ CL70 kg adult
 ðWTfor age and length=70Þ0:75 ð5Þ
CL obeseð Þ adolescent ¼ CLnonobese adolescent þ ðZ  WTexcessÞ
ð6Þ
in which CLnon-obese adolescent represents the clearance
estimate of adolescents without overweight, CL70kg adult
represents the population clearance of an adult weighing
70 kg, WTfor age and length represents developmental weight,
0.75 is the scaling factor previously proposed by the US
FDA for scaling clearance from adults to adolescents [26],
CL(obese) adolescent is the individual clearance estimates of
(obese) adolescents, and Z is the linear influence of
WTexcess in this function.
3 Results
3.1 Patients and Data
In total, 23 patients participated in the pharmacokinetic
study. One patient was excluded from the analysis because
of interference of comedication at the metformin peak of
the chromatogram of the drug assay. In total, 22 patients
were included in the analysis, from which a total of 122
metformin serum samples were available. Three patients
were receiving oral metformin 500 mg and 19 patients
were receiving oral metformin 1000 mg. Table 1 presents a
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summary of all patient characteristics, and Table 1 in the
Electronic Supplementary Material (ESM) presents the
allele frequencies of the OCT1 and MATE1 polymor-
phisms, showing that all polymorphisms were in line with
the HW equilibrium.
3.2 Observed Metformin Concentrations
The absorption of metformin in overweight and obese
adolescents proved variable, with a median time to maxi-
mum plasma concentration (Tmax) of 120 min (range
60–240) and a median maximum plasma drug concentra-
tion (Cmax) of 1.80 mg/l (range 0.79–3.45). In nine
patients, fast absorption was observed, with a Tmax of
60 min. The median dose-standardized (1000 mg) AUC0–8
and AUCinf of metformin in 22 overweight and obese
adolescents was 603.5 mg 9 min/l (range 286.7–1118.2)
and 802.7 mg 9 min/l (range 322.8–2568.8), respectively.
Dose-standardized AUC0–8 and AUCinf of metformin sig-
nificantly decreased with TBW (r = - 0.46, p = 0.032,
and r = - 0.47, p = 0.027, respectively). Genetic variation
in the OCT1 and MATE1 transporter did not have a sig-
nificant influence on the dose-standardized AUC0–8 and
AUCinf of metformin (p[ 0.05).
3.3 Population Pharmacokinetic Model
and Internal Model Validation
A one-compartment model with first-order absorption of
metformin best described the data. The pharmacokinetic
model was parameterized in terms of oral absorption rate
constant (Ka), oral volume of distribution (V/F), and oral
clearance (CL/F) from the central compartment. Residual
variability was best described by a proportional error
model. Table 2 shows the parameter estimates of the base
model without covariates.
In the covariate analysis, a significant influence of TBW
and LBW according to the equation of Peters et al. [21]
were found for CL/F of metformin in a linear manner
(p\ 0.01, - 6.6 DOFV, and - 7.6 DOFV), upon which
the covariate model with TBW was chosen as final model.
Figure 1 shows the Empirical Bayes estimates (EBEs) for
CL/F of metformin together with the covariate function of
the final model. Renal function determined by eGFR was
not a significant covariate for CL/F, which may also be
because no children with eGFR\ 80 ml/min could be
included in this study. No other covariates were identified
as a significant covariate for any of the pharmacokinetic
parameters (p[ 0.05).
Genetic polymorphisms of the OCT1 and MATE1
transporter or any combination of genotypes were not
significantly influential on any of the pharmacokinetic
parameters (p[ 0.05). OCT1 haplotype (the four SNPs
rs72552763, rs12208357, rs34130495, rs34059508)
showed a trend with Ka, but problems occurred with the
minimization and the Ka could not be estimated with
adequate precision.
Table 2 summarizes the parameters of the final model,
and Fig. 1 in the ESM shows the goodness-of-fit plots of
metformin. The bootstrap analysis confirms the results of
the model, with parameter estimates and eta estimates
within 8.5 and 14%, respectively, compared with those
obtained within the original dataset (Table 2). In addition,
prediction-corrected VPC (pcVPC) for metformin indi-
cated good predictive performance with good agreement
between observed data and model-simulated confidence
Table 1 Demographic
parameters of 22 overweight
and obese adolescents
Characteristic Overweight and obese adolescents (n = 22)
Female/male (n) 16/6
Overweight/obese 5/17
Age (years) 14.5 ± 1.8 (11.1–17.5)
Body weight (kg) 79.3 ± 13.9 (54.7–104.9)
BMI (kg/m2) 29.1 ± 4.4 (22.9–39.3)
BMI-SDS 2.8 ± 0.6 (1.7–4.0)
Waist–hip ratio 1.0 ± 0.06 (0.9–1.1)
LBW (kg) eq. Janmahasatian et al. [19] 49.0 ± 8.7 (35.3–71.1)
LBW (kg) eq. Foster et al. [20] 48.6 ± 8.6 (35.4–72.8)
LBW (kg) eq. Peters et al. [21] 55.5 ± 7.5 (41.7–71.0)
Creatinine (lmol/l) 54.5 ± 7.0 (44–69)
eGFR (ml/min/1.73 m2) [22] 111.8 ± 12.2 (94.1–135.8)
Values are expressed as mean ± standard deviation (range) unless specified otherwise
BMI body mass index, BMI-SDS body mass index standard deviation score, eGFR estimated glomerular
filtration rate, eq. equation, LBW lean body weight
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intervals for the median, 2.5th and 97.5th percentiles
(Fig. 2).
To further analyze the influence of (over)weight on the
CL/F of metformin, Fig. 3 shows clearance versus devel-
opmental weight (WTfor age and length) and versus excess
Table 2 Population pharmacokinetic parameters of the base model, excess weight covariate model, and final covariate model for metformin in
22 overweight and obese adolescents and results from a bootstrap analysis of the final model (995/1000 resamples successful)
Parameter Base model
(RSE%)
Excess weight model
(RSE%)
Final covariate model
(RSE%)
Bootstrap (95% CI)
CL/F (l/min) 1.21 (7) – – –
CL/F = CL/F70kg 9 (WTfor age and length/
70)0.75 ? (Z 9 WTexcess)
CL/F70kg – 1.16 (16) – –
Z – 0.011 (52) – –
CL/F = CL/F75.8kg 9 (1 ? V 9 (TBW - 75.8)
CL/F75.8 kg – – 1.17 (6) 1.18 (1.04–1.36)
V – – 0.0138 (44) 0.0126
(0.0035–0.0291)
V/F (L) 488 (10) 486 (10) 485 (10) 481.8 (396.8–607.8)
Ka (min-1) 0.0253 (25) 0.025 (25) 0.0248 (25) 0.0252
(0.0159–0.0563)
Interindividual variability (%)
CL/F 31.6 (29) [4] 26.5 (32) [6] 26.8 (31) [6] 24.8 (5.5–40.3)
V/F 37 (17) [14] 36.5 (17) [14] 36.2 (16) [14] 33.8 (18.2–46.4)
Ka 74.2 (21) [31] 71.4 (22) [32] 70.3 (22) [32] 65.4 (26.7–132.9)
Residual variability (%)
Proportional error 21.7 (25) [19] 21.8 (25) [18] 21.8 (25) [18] 22.0 (16.1–27.5)
OFV - 134.4 - 140.8 - 141.0 - 150.7 (- 204.4 to
- 108.0)
CI confidence interval, CL/F oral clearance, Ka absorption rate constant, OFV objective function value, RSE relative standard error, TBW total
body weight, V/F oral volume of distribution, WTexcess excess body weight, WTfor age and length developmental weight
TBW (kg)
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Fig. 1 Empirical Bayes estimates for oral clearance (CL/F) of
metformin versus total body weight (TBW) with the covariate
relation between CL/F and TBW for the final covariate model
Fig. 2 Prediction-corrected visual predictive checks of the final
model for metformin. Observed concentrations are shown as blue
circles with solid, lower and upper dashed red lines showing the
median, 2.5th and 97.5th percentiles of the observed data, respec-
tively. The shaded areas represent 95% confidence intervals for the
median, 2.5th and 97.5th percentiles of simulated concentrations
(n = 1000), based on the original dataset
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body weight (WTexcess) (Fig. 3a, b), with positive trends
for both weight measures (DOFV - 5.5 and - 4.2,
respectively; p\ 0.05). No significant trend was observed
for %WTexcess (p[ 0.05). To capture the contribution of
these different weight measures in obese adolescents, an
excess weight covariate model (Eqs. 5, 6) was applied, in
which WTfor age and length scaled on the basis of 70 kg to the
power of 0.75 (Eq. 5) [26], whereas a separate function
was estimated for WTexcess (Eq. 6). Figure 4 and Table 2
show the results of this approach in which the final
covariate model for clearance was replaced by the excess
weight covariate model. They illustrate that
WTfor age and length scales allometrically to the power of
0.75, with an additional increase in clearance depending on
WTexcess (varying between 0 and 50 kg). Both the excess
weight covariate model (Fig. 4 and Table 2) and the final
covariate model (Table 2) performed similarly in describ-
ing the data in terms of OFV (- 140.8 vs. - 141.0;
p[ 0.05) and goodness-of-fit plots.
4 Discussion
This study aimed to determine the pharmacokinetics of
metformin in overweight and obese adolescents in view of
the increasing use of metformin for obesity in children, in
whom adult dosages are often used. This study shows that
the AUC decreases and the CL/F of metformin increases
significantly with TBW in obese adolescents (Fig. 1). The
increase in CL/F can be explained by both
WTfor age and length and WTexcess (Fig. 3a, b), for which an
excess weight covariate model was proposed in which
WTfor age and length scaled allometrically to the power of
0.75 and a separate function for WTexcess was estimated.
This excess covariate weight model was applied because
the interrelation between growth, age, and obesity in obese
children and adolescents complicates a systematic covari-
ate analysis [24, 27].
When the current pharmacokinetic parameters of met-
formin in overweight and obese adolescents are compared
with literature values of non-obese children and (obese)
adults (Table 3), the dose-standardized AUC value we
report here in overweight and obese adolescents proved
about two times lower than in non-obese children [7].
However, this AUC is around the same as in obese T2DM
adolescents [8] and healthy adult subjects [8], and similar
to or higher than in obese adults [28] (Table 3). These
results indicate that obese adolescents have a higher
clearance than their non-obese counterparts [7] (Table 3),
whereas, within the obese adolescent population, CL/F in-
creased even further in more severely obese individuals
WTfor age and length (kg)
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baFig. 3 Empirical Bayes
estimates for a oral clearance
(CL/F) of metformin versus
developmental weight
(WTfor age and length) and
b excess body weight (WTexcess)
of the base model
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Fig. 4 Oral metformin clearance (population prediction [line] and
empirical Bayes estimates [triangles]) from 22 overweight and obese
adolescents versus WTfor age and length for different WTexcess levels
(i.e., 15, 30, and 50 kg, dark grey/black lines). Population values for
oral clearance are composed of the clearance of non-obese adoles-
cents (WTexcess 0 kg, light grey dotted line) plus an increase related to
WTexcess according to Eqs. (5) and (6). Observed individual values of
obese adolescents are represented by triangles with grey/black scales
varying according to the degree in WTexcess. WTexcess excess body
weight, WTfor age and length developmental weight
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(Fig. 1). The CL/F value in obese adolescents seems
comparable to the value in non-obese adults [29] and
similar to or lower than that in obese adults [28] (Table 3).
Explanations for the higher CL/F in overweight and
obese adolescents versus non-obese children may differ.
First, a higher tubular secretion of metformin by induced
OCT2 and MATE1/MATE2K transporters in the kidney
[9, 10] can be postulated in obese patients. This hypothesis
is supported by our excess weight model, which shows an
increase in CL/F with WTexcess (Fig. 3b) within the pop-
ulation of obese adolescents. Moreover, studies with
intravenous procainamide, ciprofloxacin, and cisplatin,
which are all primarily eliminated via tubular secretion,
also show a higher clearance in obese adults than in non-
obese adults [30]. These drugs are also renally transported
by the OCT system: procainamide by OCT1–3 [31],
ciprofloxacin by OCT and OAT (organic anion transporter)
[31], and cisplatin by OCT2 [32]. In contrast, obese rodent
models provide no basis for this hypothesis. High-fat-diet-
induced mice do show a trend in increased OCT2 renal
messenger RNA (mRNA) expression but no difference in
OCT1 expression [33]. Ob/Ob and db/db mice also show
no difference in renal mRNA expression of the OCT1
transporter and even a decrease of the renal OCT2 and
MATE1 transporter [34–36]. However, these ob/ob and db/
db mice models may not be representative for obese
patients, since these mice do not produce leptin or have no
functional leptin receptor, and leptin may act on renal cells
to regulate gene expression [33]. It is difficult to determine
the net result of the various effects of obesity on the reg-
ulation of transporter expression in these rodent models
[37], as pro-inflammatory cytokines, insulin, leptin, and
cholesterol all have opposing effects on mRNA expression
of the transporters [37]. In addition, renal transporters
(OCT1-2 and MATE1/MATE2K) should be considered as
a whole because they work together in the excretion of
metformin, and one transporter can compensate the other
[34]. Hence, our suggested increase in active tubular
secretion by increased activity of the renal transporters in
obese adolescents warrants further study. Another expla-
nation for the higher CL/F in obese adolescents could be a
decreased bioavailability (F) in obese adolescents as a
result of a decreased expression or activity of the intestinal
transporters of metformin (i.e., OCT1, PMAT, OCT3).
However, no literature is available about changes in
intestinal transporter expression or activity with obesity, so
this hypothesis remains rather speculative. Lastly, the
higher CL/F in obese adolescents versus non-obese
Table 3 Pharmacokinetic parameters of oral metformin in overweight and obese adolescents from this study compared with literature values
from different patient populations
Population Study
design
TBW (kg) Age (years) AUCa
(mg 9 min/l)
CL/F (l/min) V/F (l) Ka (min-1)
Obese adolescents from this
study
Fasted 79.3 ± 13.9 14.5 ± 1.8 AUC0–inf
460.5 ± 223
AUC0–8
316.5 ± 101.6
1.17b 485b 0.0248b
Non-obese children [7] Dinner 33.3 ± 2.7 9.5 ± 0.1 AUC0–12
816.2 ± 57.8
0.55 ± 0.55c 185 ± 11.7d 0.0175 ± 0.0045
Obese adolescents with T2DM
[8]
Breakfast 98 ± 25 (12–16) AUC0–inf
378.7 ± 1.6
1.32e – –
Healthy adults [8] Breakfast 91 ± 21 (20–45) AUC0–inf
398 ± 1.7
1.26e – –
Healthy adults and adults with
T2DM [29]
– 71 ± 14
89 ± 16
27 ± 6
56 ± 5
– 1.27 ± 0.27
1.32 ± 0.11
559 ± 163
648 ± 13.8
–
Obese adults [28] Fasted 114.6 ± 26.1 43.5 ± 11.7 AUC0–inf
342 ± 108
1.46e 114.6 ± 45.8f –
Values are expressed as mean ± standard deviation (range) unless specified otherwise
AUC0–12 AUC concentrations from 0 to 12 h after dose, AUC0–8 area under the curve concentrations from 0 to 8 h after dose, AUC0–inf AUC until
infinity, CL/F oral clearance, Ka absorption rate constant, T2DM type 2 diabetes mellitus, TBW total body weight, V/F oral volume of distribution
aDose standardized (500 mg) AUC
bPopulation mean
cReported clearance of 0.33 ± 0.033 with fixed bioavailability of 60%
dReported volume of 111 ± 7 with fixed bioavailability of 60%
eCalculated by CL/F = dose/AUC
fReported weight normalized V/F of 1.0 ± 0.4 l/kg
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children may also to some extent be explained by differ-
ence in age (11–17.5 vs. 9 years, respectively). However,
as this difference in age is small, this study suggests, in our
opinion, that the increase in CL/F of metformin in obese
adolescents may be explained by an increase in clearance
or a decrease in oral bioavailability resulting from an
increase or decrease in the activity in renal or intestinal
transporters, respectively. Since the value for CL/F we
report in obese adolescents is higher than in non-obese
children [7] and comparable to the value in healthy adults
and adults with T2DM [29], the maximum recommended
dose of metformin 2 g for children may be considered to be
increased to the maximum dose in adults (i.e., 3 g per day)
where clinical response is lacking.
In this study, we could not identify an influence of
genetic polymorphisms in the OCT1 and MATE1 trans-
porter on the pharmacokinetics of metformin. It is likely
that a larger number of patients is needed to accurately test
this influence. Stocker et al. [38] was unable to identify an
influence of the MATE1 promoter variant on the pharma-
cokinetics of metformin, whereas two other studies did find
an influence of genetic variation in the OCT1 transporter on
the pharmacokinetic parameters of metformin [39, 40].
Stocker et al. [38] concluded that MATE1 and MATE2
transporters work together in the renal elimination of
metformin and that genetic variants in MATE and OCT
transporters should be considered together when deter-
mining the genetic determinants of renal elimination of
metformin. For future studies, it would be interesting to
evaluate the genetic variants of OCT1-3 and MATE1-2
together. In addition, it is of special interest to evaluate the
genetic variants of the intestinal transporters of metformin
(i.e., OCT1, OCT3 and PMAT) on the bioavailability [39]
and oral absorption of metformin, since the oral absorption
of metformin showed large interindividual variability in
our data.
There are some limitations to this study. First, no non-
obese adolescents were included because this pharma-
cokinetic study was part of a randomized double-blind
controlled trial on metformin in obese adolescents with
insulin resistance [11], precluding a head-to-head com-
parison with the obese adolescents. Second, our patients
received metformin in a fasted state because, for ethical
reasons, the pharmacokinetics study was performed during
an OGTT for which a venous line was inserted for clinical
purposes. In clinical practice, patients take metformin with
food and as such our Ka may differ from that in other
studies. Oral absorption varied widely between the obese
adolescents. Nine adolescents had a very fast absorption,
with a Tmax of 60 min, whereas the mean Tmax in non-obese
children was reported to be 2.4 h [7]. This difference may
be explained by the fasted state of the obese adolescents or
by the state of obesity.
5 Conclusion
We have shown that the CL/F of metformin increases
significantly with TBW in overweight and obese adoles-
cents. The increase in CL/F is explained by both
WTfor age and length and WTexcess, for which an excess
weight model was proposed, in which WTfor age and length
scaled allometrically to the power of 0.75 and a separate
function for WTexcess was estimated. Compared with the
literature, our CL/F value in obese adolescents is higher
than in non-obese children, comparable to that in non-
obese adults, and similar to or lower than that in obese
adults. These results indicate that adult dosages of met-
formin could be considered in obese adolescents if pedi-
atric dosages have been therapeutically ineffective.
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